Compounded tirzepatide for PCOS: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, @ariannasoraya is documenting the start of a compounded tirzepatide regimen at 5mg, framing it through the lens of PCOS and insulin resistance management. The video likely positions tirzepatide as a logical treatment choice for PCOS-related metabolic dysfunction, probably referencing improvements in blood sugar, weight, and hormonal symptoms. She notes an absence of side effects in the early days, which is a common early-experience report that gets heavy engagement on GLP-1 content. The implicit message here is that compounded tirzepatide is a reasonable, accessible option for women with PCOS, and that starting doses are well-tolerated. This is a category of content that generates real influence: PCOS-tagged GLP-1 videos consistently outperform general weight loss content on TikTok, and first-person experience posts shape treatment expectations for a large audience of women who are often underserved by conventional care.

What does the science actually show?

Tirzepatide's metabolic effects are real and well-documented. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 10-15mg produced 20.9% mean body weight reduction over 72 weeks in adults with obesity. For insulin resistance specifically, tirzepatide acts on both GIP and GLP-1 receptors, producing improvements in HOMA-IR and fasting insulin that exceed semaglutide in head-to-head comparisons (Frias et al., 2021, Lancet). The PCOS-specific evidence is still thin. A 2023 pilot study (Cena et al., Journal of Clinical Endocrinology and Metabolism) showed GLP-1 receptor agonists reduced androgen levels and improved menstrual regularity in women with PCOS, but tirzepatide-specific PCOS trials are not yet published at scale. The metabolic logic is sound: reducing insulin resistance in PCOS has downstream effects on LH/FSH ratios and androgen production. But extrapolating SURMOUNT data to PCOS management as a primary indication involves a real evidence gap that most TikTok content glosses over entirely.

Where does the social media noise diverge from clinical reality?

The "no side effects yet" framing is where things get clinically misleading, not because she's lying, but because days one through seven on tirzepatide are genuinely not predictive of what happens at dose escalation. The GI side effect profile, nausea, vomiting, delayed gastric emptying, typically emerges at higher doses or during titration steps. SURMOUNT-1 reported nausea in 31.1% and vomiting in 19.2% of participants at therapeutic doses. Anchoring an audience's expectations to a honeymoon week sets people up for surprise and potential discontinuation when titration begins. The compounded tirzepatide angle is also worth flagging. Compounded versions are not FDA-approved and are not therapeutically equivalent to Zepbound or Mounjaro. Concentration, excipient formulation, and sterility standards vary by compounding pharmacy. The FDA has issued repeated warnings about compounded tirzepatide quality concerns. Presenting compounded access casually, without those caveats, misleads an audience that may not understand the regulatory distinction.

What should you actually know?

If you have PCOS and insulin resistance, GLP-1 and dual GIP/GLP-1 agonists are genuinely interesting therapeutic options, but they are not approved for PCOS as an indication. Off-label use requires a real clinical relationship, not just a telehealth prescription form. The absence of early side effects is not a green light to assume the rest of a titration will be smooth. Start low, go slow protocols exist because dose escalation is where most people encounter GI adverse events. On the compounded drug question: the FDA removed tirzepatide from its drug shortage list in late 2024, which means compounding pharmacies operating under shortage exemptions are now on shakier legal and regulatory ground. You should ask your prescriber directly whether the pharmacy they use is 503A or 503B accredited and what third-party testing they perform. Anyone presenting compounded GLP-1s as equivalent to brand-name products is either uninformed or selling something. The metabolic case for tirzepatide in PCOS is biologically plausible and worth discussing with an endocrinologist or reproductive medicine specialist, not a TikTok comment section.